- Conditions
- Psoriasis
- Interventions
- SFA002
- Drug
- Lead sponsor
- SFA Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 230
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Apremilast, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 49 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- ABT-874, etanercept, placebo
- Biological · Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 35 more
- Conditions
- Psoriasis
- Interventions
- clobetasol propionate spray 0.05%, calcitriol ointment
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 12
- States / cities
- San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- secukinumab 150 mg, secukinumab 300 mg, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more
- Conditions
- Psoriasis
- Interventions
- Apremilast, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 23 more
- Conditions
- Plaque Psoriasis
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- East Windsor, New Jersey • New York, New York
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- NDI-034858 study drug, Placebo
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 49 more
- Conditions
- Psoriasis
- Interventions
- Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
- Conditions
- Moderate to Severe Palmoplantar Psoriasis
- Interventions
- secukinumab 150 mg, secukinumab 300 mg, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
- Conditions
- Plaque Psoriasis
- Interventions
- TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,099 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Psoriasis
- Interventions
- Injections of tildrakizumab
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- San Diego, California • Grandville, Michigan
- Conditions
- Moderate to Severe Chronic Plaque-type Psoriasis
- Interventions
- secukinumab 150 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more
- Conditions
- Psoriasis
- Interventions
- Etanercept, Placebo injections
- Biological · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Active Plaque Psoriasis
- Interventions
- VB-201, Placebo
- Drug · Other
- Lead sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 10
- States / cities
- Boston, Massachusetts • Haverhill (Boston), Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Plaque Psoriasis
- Interventions
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
- Conditions
- Psoriasis
- Interventions
- IDP-122 Lotion
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Fountain Valley, California • Thousand Oaks, California • Doral, Florida + 3 more
- Conditions
- Scalp Psoriasis
- Interventions
- clobetasol propionate spray 0.05%, Vehicle spray
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Evansville, Indiana • New York, New York + 1 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- bimekizumab, ustekinumab, placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more
- Conditions
- Moderate to Severe Chronic Plaque-type Psoriasis
- Interventions
- secukinumab low dose, secukinumab high dose
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more